Fig. 4: Mcl-1 and AKT/PI3Kβ inhibitor combination rapidly induces apoptosis in PTEN-deficient breast cancer cells. | Oncogene

Fig. 4: Mcl-1 and AKT/PI3Kβ inhibitor combination rapidly induces apoptosis in PTEN-deficient breast cancer cells.

From: AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

Fig. 4

A Crystal violet staining in EVSA-T and HCC70 cells treated with the indicated drugs. B Proliferation of EVSA-T and HCC70 cells treated with AZD5991, AZD8186 or in combination for 3 days. Cells were counted every 24 h. Data are mean ± SD; n = 3. C, D Measurement of apoptosis induction in EVSA-T and HCC70 cells treated with time course of AZD5991, AZD8186 or combination for the times indicated and measured by Annexin V staining (C), or western blot analysis of cleaved PARP and PI3K pathway effector (pAKT S473) (D). Data are mean ± SD; n = 3. Data shown in D are representative of two independent experiments.

Back to article page